Cargando...
Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study
OBJECTIVES: Two oral targeted therapies, gefitinib and erlotinib, were first approved and then launched into the market for treatment of late-stage non-small cell lung cancer (NSCLC) in Taiwan in 2003 and 2006, respectively. The aim of this study were to determine the trends in lung cancer burden an...
Gardado en:
| Publicado en: | BMJ Open |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7223022/ https://ncbi.nlm.nih.gov/pubmed/32393610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-033427 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|